Articles related to PharmEste

Partnering spotlight: PharmEste advances neuropathic pain therapy to phase I

February 23, 2009 - Conference: - Company:

“V377 is the lead product coming out of PharmEste’s technology platform for the treatment of neuropathic pain that is expected to enter Phase I clinical trial in June, 2009” said Claudio Semeraro, former investor in biotechnology companies with Z-Cube, today the chief executive officer of PharmEste.
“Pharmeste is a biotech company bringing together know-how in TRPV1 Read more »

Newsletter

Subscribe to partneringNEWS
An online journal for executives in the life sciences, partneringNEWS™ is focused on the people behind the deals. Putting a human face to a collaboration agreement gives business development professionals the ability to get behind the headlines.

Sign up today to the free newsletter and never miss any new content.